Product nameAnti-53BP2/ASPP2 antibody
See all 53BP2/ASPP2 primary antibodies
DescriptionRabbit polyclonal to 53BP2/ASPP2
Tested applicationsSuitable for: WB, IP, IHC-Pmore details
Species reactivityReacts with: Human
Predicted to work with: Horse, Cow, Dog, Pig, Chimpanzee, Rhesus monkey, Gorilla, Orangutan
Synthetic peptide mapping to a region between residue 425 and 475 of human 53BP2/ASPP2 using the numbering given in entry NP_001026855.1
- Whole cell lysate from HeLa or 293T cells
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.09% Sodium azide
Constituents: 1.815% Tris, 1.764% Sodium citrate, 0.021% PBS
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab70548 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000 - 1/10000. Detects a band of approximately 170 kDa (predicted molecular weight: 125 kDa).|
|IP||Use at 2-5 µg/mg of lysate.|
|IHC-P||Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionRegulator that plays a central role in regulation of apoptosis and cell growth via its interactions. Regulates TP53 by enhancing the DNA binding and transactivation function of TP53 on the promoters of proapoptotic genes in vivo. Inhibits the ability of APPBP1 to conjugate NEDD8 to CUL1, and thereby decreases APPBP1 ability to induce apoptosis. Impedes cell cycle progression at G2/M. Its apoptosis-stimulating activity is inhibited by its interaction with DDX42.
Tissue specificityWidely expressed. Expressed in spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocyte. Reduced expression in breast carcinomas expressing a wild-type TP53 protein. Overexpressed in lung cancer cell lines.
Sequence similaritiesBelongs to the ASPP family.
Contains 2 ANK repeats.
Contains 1 SH3 domain.
DomainThe ankyrin repeats and the SH3 domain are required for a specific interactions with TP53.
Cellular localizationCytoplasm > perinuclear region. Nucleus. Predominantly found in the perinuclear region. Some small fraction is nuclear. Sequester in the cytoplasm on overexpression of DDX42.
- Information by UniProt
- 53BP2 antibody
- Apoptosis stimulating of p53 protein 2 antibody
- Apoptosis stimulating protein of p53 2 antibody
All lanes : Anti-53BP2/ASPP2 antibody (ab70548) at 0.04 µg/ml
Lane 1 : Whole cell lysate from HeLa cells at 50 µg
Lane 2 : Whole cell lysate from HeLa cells at 15 µg
Lane 3 : Whole cell lysate from HeLa cells at 5 µg
Lane 4 : Whole cell lysate from 293T cells at 50 µg
Developed using the ECL technique.
Predicted band size: 125 kDa
Observed band size: 170 kDa why is the actual band size different from the predicted?
Exposure time: 30 seconds
1mg whole cell lysate from HeLa cells was immunoprecipitated with ab70548 at 3ug/mg of lysate(lane 1) or a control IgG (lane 2). Fr the subsequent blot, 20% of immnunoprecipitate was loaded per lane, and probed with ab70548 at 1ug/ml. Detection: chemiluminescence with exposure time of 30 seconds
IHC image of ab70548 staining in normal human skin formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab70548, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
ab70548 has not yet been referenced specifically in any publications.